Literature DB >> 9596297

Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.

J G Pareja1, R Garland, H Koziel.   

Abstract

STUDY
OBJECTIVE: To examine the use of adjunctive corticosteroids in cases of severe Pneumocystis carinii pneumonia (PCP) in non-HIV-infected adult patients.
DESIGN: Retrospective review of medical records.
SETTING: Tertiary care urban teaching hospital. PATIENTS: Review identified 31 consecutive histologically confirmed primary cases of adult non-HIV-related PCP. Complete records were available for 30 patients, including 20 male and 10 female patients with a mean age of 58.3+/-15 years (+/-SD). Underlying conditions included organ transplantation (n=13), long-term immunosuppressive therapy (n=9), and chemotherapy for malignancy (n=8). All patients had documented PO2 <65 mm Hg or arterial oxygen saturation <90% on room air.
INTERVENTIONS: Following the identification of P carinii, in addition to trimethoprim-sulfamethoxazole or pentamidine therapy, 16 patients received increased steroids (> or =60 mg prednisone daily equivalent; increased high-dose steroid group), whereas 14 patients were maintained on a regimen of low doses (< or =30 mg prednisone equivalent daily) or had steroid therapy tapered (low-dose steroid group).
RESULTS: The increased high-dose steroid group demonstrated a shorter required duration for mechanical ventilation (6.3+/-6 days vs 18.0+/-21 days; p=0.047), a shorter duration of ICU admission (8.5+/-7 days vs 15.8+/-8 days; p=0.025), and a shorter duration of supplemental oxygen use (10.0+/-4 vs 32.2+/-33; p=0.05). The hospital duration to discharge for the nine survivors in each group favored the use of corticosteroids (15.4+/-5 days vs 36.3+/-33 days; p=0.077). Similar rates were observed for intubation (75% vs 57%; p=0.442) and in-hospital mortality (44% vs 36%; p=0.722).
CONCLUSIONS: These preliminary data suggest that high-dose adjunctive corticosteroids may accelerate recovery in cases of severe adult non-HIV PCP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596297     DOI: 10.1378/chest.113.5.1215

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  43 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  Fatal Pneumocystis jirovecii pneumonia in a HIV-negative adult.

Authors:  Toufik Mahfood Haddad; Saraschandra Vallabhajosyula; Muhammad Sarfraz Nawaz; Renuga Vivekanandan
Journal:  BMJ Case Rep       Date:  2015-08-26

3.  Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation.

Authors:  C Annaloro; A Della Volpe; P Usardi; G Lambertenghi Deliliers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

Review 4.  [Pneumonias and immunosuppression].

Authors:  K Dalhoff; J Marxsen; J Steinhoff
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

5.  Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients.

Authors:  Benton Ng; Anne Dipchand; David Naftel; Paolo Rusconi; Gerard Boyle; Theo Zaoutis; R Erik Edens
Journal:  Pediatr Transplant       Date:  2011-12

6.  Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients.

Authors:  H A Torres; R F Chemaly; R Storey; E A Aguilera; G M Nogueras; A Safdar; K V I Rolston; I I Raad; D P Kontoyiannis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

7.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01

8.  Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.

Authors:  Sadhna M Shankar; Joseph J Nania
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis.

Authors:  James C Lee; Deborah C Bell; Richard M Guinness; Tariq Ahmad
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

10.  Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.

Authors:  P Nickel; M Schürmann; H Albrecht; R Schindler; K Budde; T Westhoff; J Millward; N Suttorp; P Reinke; D Schürmann
Journal:  Infection       Date:  2014-08-29       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.